Remedy Place's $200 NAD Injection Pen: How Wellness Clubs Are Productizing Clinical Protocols
The global wellness device market — valued at $22.4B in 2023 and projected to reach $34.7B by 2028 — has a new entrant that signals a fundamental shift in distribution architecture for clinical-grade therapeutics. Remedy Place, the Los Angeles-based social wellness club founded by Dr. Jonathan Leary, launched its at-home NAD injection pen in March 2024, marking the first time a membership-based wellness venue has commercialized its in-house protocols into a consumer device. The $200 pen delivers nicotinamide adenine dinucleotide injections subcutaneously, translating a treatment previously confined to Remedy Place's Flatiron and West Hollywood locations into a portable revenue stream that extends the brand's distribution beyond its physical footprint.
Clinical Protocol Becomes Product Line
Remedy Place's NAD pen follows a familiar premiumization playbook: take a high-margin in-clinic service, miniaturize the delivery mechanism, and reposition it as a direct-to-consumer SKU with premium branding. The pen technology itself — sourced from an undisclosed contract manufacturer specializing in auto-injector systems — utilizes a spring-loaded mechanism similar to those deployed in diabetes care, a category that shipped 8.2M smart injection devices globally in 2023 according to IQVIA data. What differentiates Remedy Place's approach is the strategic bundling: the device is sold exclusively to club members and paired with a telehealth consultation protocol that maintains the clinical positioning while enabling recurring subscription revenue through refill cartridges priced at $175 per unit.
Dr. Leary indicated in a March interview with Well+Good that peptide delivery pens are under development for Q4 2024 launch, targeting GLP-1 analogs and collagen-stimulating peptides currently offered as in-club IV drips. This portfolio expansion mirrors the trajectory of companies like Hims & Hers, which scaled from $83M revenue in 2019 to $871M in 2023 by productizing clinical weight management and sexual wellness protocols into subscription models.
Distribution Architecture Meets Regulatory Arbitrage
The NAD pen occupies a regulatory gray zone that wellness brands are increasingly exploiting — it's marketed as a vitamin supplement delivery system rather than a pharmaceutical device, sidestepping FDA premarket approval requirements that would apply to prescription injection pens. This positioning allows Remedy Place to sell directly without traditional pharmaceutical distribution gatekeepers, compressing margin structures that typically see 40-50% erosion through wholesaler and pharmacy markup. The telehealth consultation requirement provides legal coverage while maintaining the prestige positioning that justifies the price premium over oral NAD supplements available at $45-$80 per bottle from brands like Tru Niagen and Elysium Health.
The model represents a hybrid of DTC pharmaceutical strategies and luxury beauty's members-only distribution tactics — The Outset sells exclusively through Sephora and its owned channels, while Augustinus Bader maintains pricing authority through selective retail partnerships. Remedy Place's club membership ($395 monthly in LA, $295 in NYC) functions as both revenue stream and customer acquisition funnel for higher-margin product sales.
Implications for Beauty-Wellness Convergence
If Remedy Place's peptide pens materialize as projected, the beauty industry faces a new category of competition from wellness clubs that control both the clinical expertise narrative and the last-mile distribution relationship. Injectable peptides — particularly GHK-Cu and Matrixyl formulations — represent a $1.8B segment within the broader $8.4B peptide therapeutics market, and their migration from medical spas to at-home delivery systems threatens the positioning of topical prestige skincare brands that have built equity around similar ingredient claims at lower concentrations.
The strategic question for traditional beauty conglomerates becomes whether to acquire wellness club operators before their product lines scale, partner on co-developed device SKUs, or accelerate internal R&D on smart delivery mechanisms that blur the line between cosmetic and therapeutic. Estée Lauder Companies' $2.8B acquisition of Deciem in 2022 demonstrated a willingness to buy clinical credibility — the NAD pen model suggests the next wave of M&A targets may not be ingredient brands but rather the wellness venues that have already validated clinical protocols with high-net-worth consumers willing to pay for efficacy over aspiration.